Cantor Fitzgerald reiterated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Friday, Benzinga reports. Cantor Fitzgerald currently has a $50.00 price objective on the stock. Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. reiterated an overweight […]
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Dana Pizzuti sold 14,375 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $35.00, for a total value of $503,125.00. Following the sale, the insider now owns 5,911 shares in the company, […]
Cantor Fitzgerald reaffirmed their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $50.00 target price on the stock. Several other analysts have also recently issued reports on CRNX. HC Wainwright reissued a buy rating and set a $42.00 […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Dana Pizzuti sold 9,583 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $34.57, for a total transaction of $331,284.31. Following the completion of the transaction, the insider now directly owns 5,911 shares of […]